Testing 5-ALA with ultrasound for glioblastoma in both sides of the brain
Official title: TMZ + RT + 5-ALA + LIDU SDT System for Newly Diagnosed Butterfly Glioma
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This trial is testing how safe a drug plus ultrasound is for a brain tumor on both sides.
Read our full plain-language summary
What the trial team says
This study is assessing the safety and tolerability of 5-ALA- mediated Porphyrin Metabolite Activation (PoMA) with LIDU ultrasound, in patients who have just been diagnosed with bihemispheric (in both sides of the brain) glioblastoma, sometimes called butterfly glioblastoma, before they complete their standard of care chemotherapy and radiation and after their standard of care chemotherapy and radiation while they are receviing their standard of care adjuvant chemotherapy.
Key facts
- Registry number
- NCT07862647
- Stage of testing
- Phase 1
- Conditions studied
- Glioblastom WHO Grade 4, GBM, bGBM, Butterfly GBM, Bihemispheric GBM, Glioblastoma
Where it is running
This trial lists 1 site.
-
New York
- Dent Neurologic Institute (Buffalo)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.